Drug intelligence / Profile preview

losartan + atenolol + propranolol

Development stage
Discontinued
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of three antihypertensive agents: - **Losartan** is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, leading to vasodilation and reduced aldosterone secretion. - **Atenolol** is a cardioselective beta-1 adrenergic receptor antagonist (beta-blocker) that reduces heart rate and cardiac output, thereby lowering blood pressure. - **Propranolol** is a non-selective beta adrenergic antagonist (beta-blocker) that blocks both beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and renin release. This specific triple combination does not appear to be available as a single commercial product or fixed-dose formulation. Each component has established use in hypertension management but combining two different beta blockers (atenolol and propranolol) with an ARB like losartan in one regimen is highly unusual in clinical practice due to overlapping mechanisms and increased risk of adverse effects. There are no known brand names or marketed products containing all three ingredients together[1][2][3][4][5][6].

02

Targets

ADRB1 (β1)ADRB2 (β2)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on losartan + atenolol + propranolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on losartan + atenolol + propranolol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call